New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:06 EDTCRMECardiome reports Q4 EPS (53c), consensus (22c)
Reports Q4 revenue $3.9M, consensus $3.17M; The net loss in Q4 was largely due to an increase in SG&A expenses incurred to support the commercialization of BRINAVESS and AGGRASTAT.
News For CRME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2015
08:03 EDTCRMECardiome expands commercialization partnership with Eddingpharm
Cardiome announced that its subsidiary, Correvio International Sarl, has entered into an exclusive license and supply agreement with Eddingpharm to distribute and commercialize AGGRASTAT in China. Financial terms of the agreement include milestone payments and minimum annual commercial commitments. The financial terms of the agreement are not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use